Semaglutide for Alzheimer's: EVOKE Trial Results

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

The EVOKE and EVOKE+ clinical trials investigated oral semaglutide for people with early-stage Alzheimer's disease [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies].
These global trials, completed in November 2025, did not meet their main goals for slowing the progression of cognitive decline [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies].
GLP-1 medications, like semaglutide, are commonly prescribed for managing type 2 diabetes and assisting with weight loss [https://www.alz.org/blog/2025/glp-1s-and-alzheimer-s-what-you-need-to-know].
Despite not meeting primary goals, Novo Nordisk observed improvements in Alzheimer’s-related biomarkers in both EVOKE trials, suggesting a potential future role in combination therapies [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies].

Recent attention has focused on a class of drugs called GLP-1 receptor agonists, which are well-known for their roles in treating type 2 diabetes and obesity. These medications, including semaglutide, have also been explored for their potential to help treat Alzheimer's disease. The EVOKE and EVOKE+ global clinical trials specifically investigated oral semaglutide for individuals in the early stages of Alzheimer's. While the topline results, released in November 2025, indicated that these trials did not meet their primary goals for slowing cognitive decline, they still represent a significant moment in Alzheimer's research [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies]. The completion of these Phase 3 studies, which evaluated a mechanism related to the biology of aging, marks a shift in how new Alzheimer’s treatments are developed, moving towards targeting the disease's underlying pathobiology. For example, the EVOKE Plus study alone involved 495 locations across the globe, showcasing the extensive effort put into this research [https://clinicaltrials.gov/study/NCT04777409]. Researchers are now considering the possibility of semaglutide as part of a combination therapy approach, building on observations of improved Alzheimer’s-related biomarkers in the trials.

What Are GLP-1 Medications and Why Were They Studied for Alzheimer's?

GLP-1 receptor agonists are a class of medications primarily designed to help the body regulate blood sugar levels. These drugs have become widely recognized for their effectiveness in managing type 2 diabetes and supporting weight loss for individuals with obesity. The exploration into their potential for Alzheimer's disease stems from growing research suggesting these medications might have beneficial effects on the brain and nervous system.

Understanding GLP-1s

GLP-1 stands for glucagon-like peptide-1. This is a natural hormone in the body that plays a key role in metabolism. GLP-1 receptor agonists mimic the action of this hormone. When a person takes a GLP-1 medication, it helps the pancreas release more insulin when blood sugar levels are high. It also reduces the amount of glucagon released, which is a hormone that raises blood sugar. Beyond these actions, GLP-1s slow down how quickly food leaves the stomach, helping people feel fuller for longer. This combined effect helps improve blood sugar control and can lead to weight loss.

Some of the most common GLP-1 drugs that people might recognize by name include semaglutide, which is sold under the brand names Ozempic®, Wegovy®, and Rybelsus®. Another common GLP-1 is liraglutide, marketed as Victoza® and Saxenda®. Tirzepatide, known as Mounjaro® and Zepbound™, is also a GLP-1 drug, although it works on an additional receptor called GIP, making it a "dual agonist." These medications have transformed care for millions of people living with type 2 diabetes and obesity [https://www.alz.org/blog/2025/glp-1s-and-alzheimer-s-what-you-need-to-know].

The Link to Brain Health and Alzheimer's

The interest in GLP-1s for Alzheimer's disease grew from research indicating that these drugs might have effects beyond just blood sugar and weight management. Scientists started to observe that GLP-1s could potentially influence the brain and nervous system in beneficial ways. Specifically, studies suggested that these medications might reduce brain inflammation. Inflammation in the brain is a known factor in the development and progression of Alzheimer's disease. By reducing this inflammation, GLP-1s could theoretically slow down the damage to brain cells.

Furthermore, research suggested that GLP-1s could improve the health of blood vessels, including those in the brain. Healthy blood flow is vital for brain function, and problems with blood vessels are often linked to Alzheimer's and other types of dementia. Better blood vessel health could mean a more robust supply of oxygen and nutrients to brain cells, helping them function better and resist damage. Another promising area of research indicated that GLP-1s might directly protect neurons, which are the nerve cells in the brain responsible for transmitting information. Protecting these cells from damage and death is a critical goal in Alzheimer's treatment. These findings opened the door to exploring whether GLP-1s, already proven safe and effective for other conditions, could be repurposed to help treat or even prevent Alzheimer's [https://www.alz.org/blog/2025/glp-1s-and-alzheimer-s-what-you-need-to-know]. The idea was to leverage their known benefits in metabolism and inflammation to address some of the complex biological processes involved in Alzheimer's disease.

The potential for these drugs to reduce inflammation, improve blood vessel health, and protect neurons made them strong candidates for further study in the context of neurodegenerative diseases like Alzheimer's. The scientific community recognized that if GLP-1s could offer neuroprotective benefits, they might represent a new pathway for intervention, different from the amyloid-targeting drugs that have been the focus for many years. This led to the design and execution of large-scale clinical trials like EVOKE and EVOKE+, aimed at thoroughly investigating semaglutide's impact on early-stage Alzheimer's disease. The hope was that by addressing multiple aspects of brain health, GLP-1s could offer a comprehensive approach to combating this complex and devastating disease.

What Were the EVOKE and EVOKE+ Trials?

The EVOKE and EVOKE+ trials were two significant global Phase 3 clinical studies designed to investigate the potential of oral semaglutide as a treatment for early-stage Alzheimer's disease. These trials represented a major effort to explore a new therapeutic avenue for a condition that desperately needs effective treatments. The studies were carefully structured to assess whether semaglutide could slow the progression of cognitive decline and impact other markers of the disease.

Design and Scope of the Trials

EVOKE and EVOKE+ were comprehensive, multinational clinical trials. They focused specifically on individuals diagnosed with early-stage Alzheimer's disease. This stage is crucial because interventions at this point might have the best chance of slowing the disease's progression before widespread brain damage occurs. The primary goal of these trials was to determine if daily oral semaglutide could meaningfully impact the course of Alzheimer's disease. Researchers aimed to see if the medication could preserve cognitive function and daily living abilities in participants over time.

The trials were set up as randomized, double-blind, placebo-controlled studies. This means that participants were randomly assigned to either receive semaglutide or a placebo, and neither the participants nor their doctors knew which treatment they were getting. This design helps ensure that any observed effects are truly due to the medication and not to other factors. The global reach of these trials was extensive, involving numerous research sites across different countries. For example, the EVOKE Plus study alone had an impressive 495 locations where participants were enrolled and monitored [https://clinicaltrials.gov/study/NCT04777409]. These locations included several sites across the United States, such as Phoenix, Scottsdale, Sun City, and Tucson in Arizona. California also had numerous sites, including Anaheim, Lomita, Long Beach, and multiple locations in Los Angeles, Newport Beach, Panorama City, Pasadena, San Diego, Santa Ana, Sherman Oaks, and Simi Valley. Colorado also hosted sites, starting with Basalt. This broad geographical distribution helped ensure a diverse participant pool and increased the generalizability of the study results. For more details, see Alzheimer's Association GLP-1s and Alzheimer's.

The Aims of EVOKE and EVOKE+

The central aim of the EVOKE and EVOKE+ trials was to investigate whether semaglutide could effectively treat or even prevent the progression of Alzheimer's disease. Specifically, the trials were designed to measure changes in cognitive function and functional abilities over the study period. Cognitive function refers to mental processes like memory, thinking, and reasoning. Functional abilities relate to a person's capacity to perform everyday tasks, which are often significantly impacted by Alzheimer's.

Beyond these primary measures, the trials also looked at secondary endpoints, which included various biomarkers related to Alzheimer's disease. Biomarkers are biological indicators that can help track the disease's presence and progression. These could include specific proteins in the cerebrospinal fluid or changes observed in brain imaging. The researchers hoped that if semaglutide improved cognitive and functional outcomes, it would also show positive changes in these underlying biological markers. The rationale for studying semaglutide was rooted in its known metabolic and anti-inflammatory effects. The scientific community hypothesized that by addressing metabolic dysregulation, reducing brain inflammation, improving cerebrovascular health, and potentially offering neuroprotection, semaglutide could offer a novel approach to combating Alzheimer's. The completion of these trials, regardless of the primary outcome, was seen as a critical step in understanding the complex interplay between metabolic health and neurodegeneration, and in expanding the scope of Alzheimer's drug development beyond traditional targets like amyloid plaques.

What Were the Results of the Semaglutide EVOKE Trials?

Novo Nordisk, the pharmaceutical company behind semaglutide, released the topline results from their Phase 3 EVOKE and EVOKE+ trials in November 2025. These results provided crucial insights into semaglutide's effectiveness in individuals with early-stage Alzheimer's disease. While the trials generated significant attention, the primary outcomes were not what many had hoped for.

Primary Endpoints Not Met

The most significant finding from the EVOKE and EVOKE+ trials was that they did not meet their primary endpoints [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies]. A "primary endpoint" in a clinical trial refers to the main goal or outcome that the study is designed to measure. For the EVOKE trials, this primary endpoint was likely a measure of cognitive decline or functional ability, such as scores on specific memory or daily living assessments. Not meeting this endpoint means that semaglutide, when used as a standalone treatment, did not demonstrate a statistically significant benefit in slowing the progression of cognitive decline in people with early Alzheimer's compared to a placebo.

This outcome means that, based on these specific trial designs and measures, semaglutide did not achieve the desired level of efficacy to be considered a direct treatment for Alzheimer's disease on its own. The completion of these studies, despite the primary results, is still important. It helps guide future research and understanding of the disease. It provides clear data on one specific approach, which is crucial for the scientific process. The data from these trials will be presented in more detail at upcoming scientific conferences, such as CTAD (Clinical Trials on Alzheimer’s Disease), where researchers will be able to analyze the full dataset and discuss its implications.

Improvement in Biomarkers

Despite the disappointment regarding the primary endpoints, the trials did reveal some interesting secondary findings. Novo Nordisk reported that there was an improvement in Alzheimer’s-related biomarkers in both the EVOKE and EVOKE+ trials [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies]. Biomarkers are measurable indicators of a biological state or condition. In Alzheimer's disease, these can include changes in specific proteins in the brain or cerebrospinal fluid, or structural changes observed through brain imaging. For example, some common Alzheimer's biomarkers include amyloid-beta and tau proteins.

An improvement in these biomarkers, even without a significant impact on cognitive decline, suggests that semaglutide might be having some biological effect on the disease process. This observation is significant because it indicates that the drug is interacting with the disease in some way, even if that interaction was not strong enough to translate into a measurable clinical benefit on its own. Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), commented on these findings, stating, "Novo has noted an improvement of Alzheimer’s-related biomarkers in both trials. We look forward to seeing further results at CTAD, as this may suggest a path forward for semaglutide as part of a combination therapy approach." This perspective highlights that while semaglutide might not be a standalone cure, its influence on biomarkers could point to its utility in a more complex treatment strategy. The full details of these biomarker improvements are eagerly awaited by the scientific community, as they could unlock new insights into how GLP-1 drugs interact with the underlying pathology of Alzheimer's disease.

What Do These Results Mean for Alzheimer's Treatment?

The results from the EVOKE and EVOKE+ trials, while not meeting their primary endpoints, mark a crucial moment in Alzheimer's research. They signal a fundamental shift in how the scientific community is approaching the development of new treatments for this complex disease. The focus is expanding beyond single targets to encompass the complete biology of Alzheimer's.

A Shift in Treatment Strategy

The outcome of the semaglutide trials reinforces the idea that Alzheimer's disease is incredibly complex and likely requires a multifaceted approach to treatment. For many years, much of Alzheimer's research centered on targeting amyloid plaques, which are abnormal protein deposits in the brain believed to contribute to the disease. While anti-amyloid drugs have shown some success, they only address one aspect of the disease. The EVOKE trial results, by exploring a different pathway (related to metabolism and inflammation), highlight the need to look at the broader picture.

Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), emphasized this shift. He stated, "While it is disappointing that the trials did not meet their primary endpoints, they show a fundamental shift in how we approach the development of new Alzheimer’s treatments, expanding beyond amyloid to target the complete pathobiology of the disease [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies]." This perspective suggests that future treatments will likely need to address multiple underlying biological processes involved in Alzheimer's, such as inflammation, metabolic dysfunction, and vascular health, rather than just amyloid accumulation. This expansion of focus reflects a deeper understanding of the disease's true complexity. For more details, see Alzheimer's Drug Discovery Foundation EVOKE trial results.

The Need for Combination Therapies

The current landscape of Alzheimer's treatment includes drugs that target amyloid, and these have shown some benefits. Existing anti-amyloid drugs can slow cognitive decline by approximately 30% [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies]. While this is a meaningful step, it means that a significant portion, about 70%, of cognitive decline remains unaddressed by these therapies alone. This gap underscores the urgent need for additional treatments that can target other pathways and mechanisms of the disease.

Dr. Fillit further explained the importance of this multi-target approach: "Existing anti-amyloid drugs slow cognitive decline by around 30%, so therapies aimed at other pathways will be crucial as we chip away at the remaining 70%." This statement highlights that treatments like semaglutide, even if not effective as standalone agents, could still play a vital role when combined with other drugs. The strategy is similar to how cancer is treated, where a combination of different drugs targeting various aspects of the disease often yields the best results. The completion of two Phase 3 trials targeting a non-amyloid pathway, even with negative primary results, represents real momentum towards developing such combination approaches in Alzheimer's. It provides valuable data that can inform the design of future studies, helping researchers understand which pathways are most promising for combination therapies. The goal is to create a comprehensive treatment regimen that addresses the multifaceted nature of Alzheimer's, ultimately providing more substantial benefits to patients.

The shift towards combination therapies also means a broader consideration of drugs that might not have been initially developed for Alzheimer's. Medications that influence metabolism, inflammation, or vascular health, like GLP-1s, could become components of a larger treatment plan. The EVOKE results, therefore, are not an end but rather a critical data point in an ongoing journey to develop more effective and holistic treatments for Alzheimer's disease. They push the research community to think more creatively and broadly about how to tackle this challenging condition.

Can Semaglutide Still Play a Role in Alzheimer's Care?

Despite the EVOKE trials not meeting their main goals for slowing cognitive decline, the research into semaglutide's potential role in Alzheimer's care is not over. The observed improvements in Alzheimer’s-related biomarkers offer a glimmer of hope and suggest that semaglutide might still have a place, particularly as part of a more comprehensive treatment strategy. This approach mirrors how many other complex diseases, such as cancer, are managed.

Potential as Part of Combination Therapy

The fact that Novo Nordisk reported an improvement in Alzheimer’s-related biomarkers in both the EVOKE and EVOKE+ trials is a key takeaway. Even if these biological changes didn't translate into a significant slowing of cognitive decline when semaglutide was used alone, they indicate that the drug does have an effect on the underlying disease processes. This suggests that semaglutide might be more effective when combined with other therapies that target different aspects of Alzheimer's.

Imagine a situation where one drug targets amyloid plaques, another addresses tau tangles, and a third, like semaglutide, works to reduce inflammation or improve metabolic health in the brain. This multi-pronged attack could potentially yield greater benefits than any single drug alone. Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), highlighted this possibility. He stated, "Novo has noted an improvement of Alzheimer’s-related biomarkers in both trials. We look forward to seeing further results at CTAD, as this may suggest a path forward for semaglutide as part of a combination therapy approach." This idea of combination therapy is not new in medicine. For instance, in cancer treatment, patients often receive a combination of chemotherapy, radiation, and targeted drugs to achieve the best outcomes. Applying a similar strategy to Alzheimer's could be the next logical step. The EVOKE data provides valuable information about one piece of that potential puzzle.

Future Research and Insights

The full implications of the EVOKE trial results are still being analyzed. Researchers and clinicians are eagerly awaiting the detailed presentation of the data, especially concerning the biomarker improvements, at upcoming scientific conferences like CTAD. These presentations will offer deeper insights into which specific biomarkers were affected and to what extent. This detailed information will be crucial for designing future studies.

For example, if semaglutide significantly impacted markers of inflammation or vascular health, then future trials could pair it with drugs specifically designed to address amyloid or tau pathologies. This would allow researchers to test the hypothesis that combining different mechanisms of action could lead to a more robust clinical benefit. The ongoing analysis of the EVOKE data will help scientists understand the precise mechanisms through which semaglutide interacts with Alzheimer's disease. This knowledge is vital for identifying the most promising combinations and for determining the optimal timing and dosing of such combined treatments. The journey to find a cure or highly effective treatment for Alzheimer's is long and complex. Each trial, whether it meets its primary endpoint or not, adds valuable information to our collective understanding. The EVOKE trials, by showing an effect on biomarkers, have certainly contributed to this growing body of knowledge, keeping the door open for semaglutide's potential future role in Alzheimer's care.

Are GLP-1s Being Studied for Other Conditions?

Beyond their well-established uses for type 2 diabetes and weight management, and their exploration for Alzheimer's disease, GLP-1 medications are also being investigated for a range of other health conditions. The broad physiological effects of GLP-1 receptor agonists suggest they could have therapeutic potential in areas not initially considered. One particularly promising area of research involves their use in treating addiction, specifically alcohol and drug addiction.

GLP-1s and Addiction

Recent research indicates that GLP-1s show promise in treating alcohol and drug addiction [https://www.endocrine.org/news-and-advocacy/news-room/2025/glp1s-show-promise-in-treating-alcohol-and-drug-addiction]. The mechanisms behind this potential effect are still being explored, but they are thought to involve GLP-1's influence on the brain's reward pathways and its ability to reduce cravings. The idea is that by modulating these brain circuits, GLP-1s could help individuals reduce their desire for addictive substances. For more details, see ClinicalTrials.gov EVOKE Plus study details.

A significant randomized clinical trial investigated the effect of once-weekly semaglutide in adults with alcohol use disorder. The study aimed to determine if semaglutide could reduce alcohol consumption. The results were encouraging: the trial found that once-weekly semaglutide effectively reduced alcohol self-administration in these adults [https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811]. Specifically, among the 25 participants who completed the self-administration procedure, 13 were in the semaglutide group and showed a reduction in alcohol intake. This reduction was observed after 8 weeks of treatment with 0.5 mg/wk of semaglutide. The study measured outcomes like estimated grams of alcohol consumed and peak measured breath alcohol concentration (BrAC), both of which showed positive changes in the semaglutide group compared to placebo. This suggests a direct impact of the medication on alcohol-seeking behavior and consumption.

Liver Protection and Other Potential Uses

Beyond addiction, GLP-1 receptor agonists have also been found to offer protective benefits to the liver, especially during alcohol consumption. Research from the Yale School of Medicine, for instance, highlighted that GLP-1 receptor agonists protect the liver during alcohol consumption [https://medicine.yale.edu/news-article/glp-1-receptor-agonists-protect-the-liver-during-alcohol-consumption/]. This finding is particularly relevant for individuals who consume alcohol, as chronic alcohol use can lead to various forms of liver damage. The liver-protective effects of GLP-1s could be another significant therapeutic advantage, potentially mitigating some of the harm associated with alcohol intake.

The expanding research into GLP-1s underscores their versatility and the broad impact they can have on human physiology. Scientists are continually discovering new ways these medications interact with different organ systems and biological pathways. From their origins in diabetes and weight management, to their exploration in neurodegenerative diseases like Alzheimer's, and now their promising role in addiction and liver protection, GLP-1s are emerging as a class of drugs with diverse therapeutic applications. This ongoing research highlights the dynamic nature of drug discovery and the potential for existing medications to be repurposed to address a wider range of health challenges. The continued investigation into GLP-1s will likely uncover even more surprising possibilities for these powerful compounds in the future.

Frequently Asked Questions

What are GLP-1 drugs?

GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, are medications that mimic a natural hormone in the body to help regulate blood sugar. They were originally developed to treat type 2 diabetes and are also widely used for weight management. Common examples include semaglutide (Ozempic®, Wegovy®, Rybelsus®), liraglutide (Victoza®, Saxenda®), and tirzepatide (Mounjaro®, Zepbound™) [https://www.alz.org/blog/2025/glp-1s-and-alzheimer-s-what-you-need-to-know]. These drugs work by increasing insulin release, decreasing glucagon secretion, and slowing stomach emptying.

What were the EVOKE and EVOKE+ trials studying?

The EVOKE and EVOKE+ trials were two global Phase 3 clinical studies. They investigated whether oral semaglutide could effectively treat or slow the progression of early-stage Alzheimer's disease. These trials focused on measuring changes in cognitive function and daily living abilities in participants. The EVOKE Plus study alone involved 495 research locations worldwide, including sites in Arizona and California [https://clinicaltrials.gov/study/NCT04777409].

Did semaglutide work for Alzheimer's in these trials?

No, the EVOKE and EVOKE+ trials did not meet their primary endpoints, meaning semaglutide did not significantly slow cognitive decline as a standalone treatment. The topline results were released by Novo Nordisk in November 2025 [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies]. However, Novo Nordisk did note an improvement in Alzheimer’s-related biomarkers in both trials, suggesting some biological effect.

What does 'primary endpoint' mean in a clinical trial?

A primary endpoint is the main goal or outcome that a clinical trial is designed to measure. It is the specific result or effect that researchers are looking for to determine if a new treatment is effective. For the EVOKE trials, the primary endpoint was likely a measure of cognitive decline or functional abilities in people with early Alzheimer's. Not meeting this endpoint means the drug did not show a statistically significant benefit for that main goal [https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies].

Are GLP-1 drugs only used for diabetes and weight loss?

No, GLP-1 drugs are being studied for several other conditions beyond diabetes and weight loss. For example, they show promise in treating alcohol and drug addiction [https://www.endocrine.org/news-and-advocacy/news-room/2025/glp1s-show-promise-in-treating-alcohol-and-drug-addiction]. A study found that 13 out of 25 participants in a semaglutide group reduced alcohol self-administration after 8 weeks of treatment [https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811]. GLP-1 receptor agonists also protect the liver during alcohol consumption.